Idelalisib
| Overview | |
| Catalog # | bs-83035c-10-mg |
| Product Name | Idelalisib |
| Specifications | |
| Storage Buffer | Off-white solid |
| Storage Condition | -20°C |
| Target | |
| Product Information | Potent (IC50 = 2.5nM) and selective (IC50’s: PI3Ka = 820nM, PI3Kb = 565nM, PI3Kg = 89nM) PI3Kd inhibitor.1,2 Useful clinical agent for the treatment of various blood cancers. Idelalisib attenuates regulatory T cells (Treg) but not conventional T cells (Tconv) resulting in a significant increase in tumor-infiltrating antigen-specific CD8 T cells in a murine lung cancer model.3 Conversely, systemic PI3Kd inactivation antagonized anti-CTLA-4 and anti-PD-L1 treatment.4 Others have found that Idelalisib minimally influenced rituximab- and obinutuzumab-mediated Ab-dependent cellular cytotoxicity in human lymphoma cells.5 |
| Description | CAS Number: 870281-82-6 Chemical Name: 5-Fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one Molecular weight: 415.43 Formula: C21H18FN7O Solubility: DMSO (>25 mg/ml) Physical Properties: White solid Purity: >98% by HPLC NMR (Conforms) |
Powered by Bioz